Semaglutide Weight-Loss Timeline

Week 68: the main weight-management result

STEP 1 studied adults with overweight or obesity without diabetes who received weekly semaglutide 2.4 mg or placebo with lifestyle intervention. Mean body-weight change at week 68 was -14.9% with semaglutide and -2.4% with placebo. The study did not use Ozempic, oral semaglutide, or compounded formulations as interchangeable regimens.

The year after stopping

The STEP 1 extension followed a subset after semaglutide and lifestyle intervention ended. Average body weight increased by 11.6 percentage points during the following year, roughly two-thirds of prior loss according to the authors. This result is useful for a maintenance conversation because it shows what happened after the study transition.

What a useful follow-up timeline tracks

A clinical timeline includes symptoms, tolerance, weight, diabetes status when relevant, other medicines, access, and longer-term goals. Wegovy's weight-management label and Ozempic's diabetes label remain distinct, even though both products contain semaglutide.

Keep product labels separate

Wegovy is the semaglutide product with the cited weight-management label. Ozempic is labeled for type 2 diabetes and related cardiovascular and kidney-risk indications. They share an ingredient, but editorial copy should not turn that into automatic interchangeability.

Route and formulation questions belong on the oral-versus-injectable page, not in a borrowed dosing table.

A timeline should include a maintenance question

ADA guidance describes obesity pharmacotherapy as chronic treatment when clinically appropriate and supports continuing monitoring after goals are reached. The discussion includes benefit, safety, tolerance, burden, and alternatives.

That means a timeline should end with a follow-up question, not a sales claim about a finish line.

Safety comes before a scale target

Severe persistent abdominal pain, repeated vomiting, dehydration, allergic symptoms, and clinically important vision changes in a person with diabetes need prompt assessment. Those problems should not be reframed as normal milestones.

Readers should use the exact label and care team for symptom-specific decisions.

Urgent symptoms are more important than whether a weekly weight target was reached.

What the cited sources establish

STEP 1 measured weekly semaglutide 2.4 mg plus lifestyle intervention through 68 weeks in adults with overweight or obesity without diabetes. Its extension followed a subset after treatment and lifestyle intervention ended. Those results create a long-horizon evidence frame, not a validated weekly curve for Wegovy, Ozempic, oral semaglutide, or a compounded product.

STEP 1's 68-week result and its extension's one-year follow-up should be read together: one describes treatment-period weight change, and the other describes average change after study treatment ended. That context supports a maintenance conversation before access, tolerance, pregnancy plans, or preference force a decision. It also keeps Wegovy's weight-management evidence distinct from Ozempic's diabetes label and from oral-product studies.

The STEP 1 result is most useful when paired with its study frame: weekly semaglutide 2.4 mg, lifestyle intervention, adults without diabetes, and a 68-week endpoint. The extension then adds a separate maintenance signal after study treatment ended. A real follow-up timeline can track tolerance, weight, diabetes status when relevant, other medicines, and access, while keeping a different product or formulation from being folded into the same expected curve.

Questions that change the next review

A semaglutide timeline visit can connect weight change with tolerance, nutrition, activity, diabetes status, other medicines, access, and the expected label-specific follow-up. That broader review is more useful than attempting to reproduce another participant's curve or treating one quiet month as proof that treatment has failed.

A useful timeline conversation asks which outcomes matter besides weight and whether symptoms, access, diabetes care, or another medicine changed during the same period. That keeps the 68-week trial result in the right clinical frame.

Product details that still need verification

The page does not create a personal deadline, recommend dose changes, or turn STEP 1 withdrawal data into a restart plan. It also keeps Wegovy's weight-management evidence distinct from Ozempic's diabetes label and from oral-product evidence. Symptom safety takes priority over a chart milestone.

STEP 1 studied weekly semaglutide 2.4 mg plus lifestyle intervention. Withdrawal evidence matters for maintenance conversations. Wegovy and Ozempic have distinct labeled uses. A personal plateau needs a clinical review, not an unsupervised switch. Use STEP 1 to understand the evidence horizon. Do not turn a trial average into a deadline or a reason to change treatment alone.

Use the current product label and prompt clinical care for urgent symptoms or medication changes.